2.4.0.8060200 - Disclosure - Notes Payabletruefalsefalse1false falsefalsec20120401to20130331http://www.sec.gov/CIK0000890846duration2012-04-01T00:00:002013-03-31T00:00:001true 1us-gaap_NotesPayableAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Notes Payable [Abstract]2false 2us-gaap_DebtDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: times new roman; width: 100%;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; display: inline;">2.&#160;&#160;</div></td><td><div style="font-size: 10pt; font-family: times new roman; font-weight: bold; text-align: justify; margin-left: 0pt; margin-right: 0pt; text-indent: 0pt;">Notes Payable</div></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">We had no outstanding notes payable at March 31, 2013 or March 31, 2012.</div><div style="display: block; text-indent: 0pt;"><br /></div><div style="font-size: 10pt; font-family: Times New Roman; text-align: left; margin-left: 0pt; display: block; margin-right: 0pt; text-indent: 0pt;">Uroplasty BV, our subsidiary in the Neatherlands, has an ongoing&#160;agreement with Rabobank of The Netherlands for a &#8364;150,000 (approximately $192,000) credit line secured by our facility in Geleen, The Netherlands.&#160;&#160;The bank charges interest on the loan at the rate of one percentage point over the Rabobank base interest rate (4.0% base rate on March 31, 2013), subject to a minimum interest rate of 3.5% per annum.&#160;&#160;At March 31, 2013 and 2012, we had no borrowings outstanding on this credit line.</div><div style="display: block; text-indent: 0pt;"><br /></div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20,22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0Notes PayablefalseNotes PayableUnKnownUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://uroplasty.com/role/NotesPayable12